Madhi SA - Search Results

1

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.

Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Bhorat AE, et al. Among authors: madhi sa. AIDS. 2015 Jul 17;29(11):1345-54. doi: 10.1097/QAD.0000000000000689. AIDS. 2015. PMID: 25888646 Free PMC article. Clinical Trial.

2

The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia.

Ruffini DD, Madhi SA. Ruffini DD, et al. Among authors: madhi sa. AIDS. 2002 Jan 4;16(1):105-12. doi: 10.1097/00002030-200201040-00013. AIDS. 2002. PMID: 11741168

3

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. Klugman KP, et al. Among authors: madhi sa. N Engl J Med. 2003 Oct 2;349(14):1341-8. doi: 10.1056/NEJMoa035060. N Engl J Med. 2003. PMID: 14523142 Free article. Clinical Trial.

4

The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.

Madhi SA, Kuwanda L, Cutland C, Klugman KP. Madhi SA, et al. Clin Infect Dis. 2005 May 15;40(10):1511-8. doi: 10.1086/429828. Epub 2005 Apr 7. Clin Infect Dis. 2005. PMID: 15844075 Clinical Trial.

5

Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.

Madhi SA, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Madhi SA, et al. Pediatr Infect Dis J. 2005 May;24(5):410-6. doi: 10.1097/01.inf.0000160942.84169.14. Pediatr Infect Dis J. 2005. PMID: 15876939 Clinical Trial.

6

Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children.

Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Käyhty H, Klugman KP. Madhi SA, et al. Vaccine. 2005 Dec 1;23(48-49):5517-25. doi: 10.1016/j.vaccine.2005.07.038. Epub 2005 Aug 1. Vaccine. 2005. PMID: 16107294

7

Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia.

Madhi SA, Kohler M, Kuwanda L, Cutland C, Klugman KP. Madhi SA, et al. Pediatr Infect Dis J. 2006 Jan;25(1):30-6. doi: 10.1097/01.inf.0000195787.99199.4a. Pediatr Infect Dis J. 2006. PMID: 16395099 Clinical Trial.

8

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF. Madhi SA, et al. Vaccine. 2006 Mar 20;24(13):2432-9. doi: 10.1016/j.vaccine.2005.12.002. Epub 2005 Dec 20. Vaccine. 2006. PMID: 16406170 Clinical Trial.

9

Pneumococcal coinfection with human metapneumovirus.

Madhi SA, Ludewick H, Kuwanda L, Niekerk Nv, Cutland C, Little T, Klugman KP. Madhi SA, et al. J Infect Dis. 2006 May 1;193(9):1236-43. doi: 10.1086/503053. Epub 2006 Mar 17. J Infect Dis. 2006. PMID: 16586360 Clinical Trial.

10

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.

Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Madhi SA, et al. Vaccine. 2007 Mar 22;25(13):2451-7. doi: 10.1016/j.vaccine.2006.09.019. Epub 2006 Sep 20. Vaccine. 2007. PMID: 17023095 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

693 results

Search Page

Filters